HDAC9 and leukemia: In leukemia K562 and fibrosarcoma HT1080 cell lines, both of which have a very low basal SLFN11 expression, HDAC inhibitors (romidepsin and entinostat) increase SLFN11 expression and enhance sensitivity to DNA-damaging agents in SLFN11-dependent manner [26].